ZUG, Switzerland, November 9, 2026 -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis"), a global biopharmaceutical company focused on breakthrough innovations in neuro-ophthalmology and ophthalmology, today
Licaminlimab (PREDICT-1): Patient randomization is now complete in the registrational symptoms trial evaluating Licaminlimab for TNFR1-mediated dry eye disease (DED). Topline results are anticipated around year-end
Björn Tackenberg, M.D. Ph.D. FEAN FAAN, Professor of Neurology, will lead Oculis’ global integrated scientific strategy supporting the advancement of Privosegtor and its expansion into new therapeutic applications
ZUG, Switzerland, October 29th, 2026 -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis"), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo Lower NfL and GFAP levels provide objective, complementary biological
Presentation highlights new translational data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation ZUG, Switzerland, October 20, 2026 -- Oculis Holding AG (NASDAQ:OCS)
High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials Precision Medicine Approach in a Large
Licaminlimab genotype-based precision medicine approach for TNFR1-mediated dry eye disease in PREDICT-1 registrational symptoms trial on track for topline readout around year-end ZUG, Switzerland, October 7, 2026 --
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve
Oculis Announces Resignation of Lionel Carnot from Board of Directors ZUG, Switzerland, September 30, 2026 -- Oculis Holding AG (NASDAQ:OCS) ("Oculis" or the "Company"), a global biopharmaceutical
ZUG, Switzerland, August 24th, 2026 -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in
Transaction will enhance Oculis’ strategic flexibility and ownership of Privosegtor while driving long-term value creationTransaction consideration includes $3.8 million up-front cash payment at closing and up to
Company pivot to neuro-ophthalmology continues with Privosegtor positioned as lead late-stage asset through the registrational PIONEER program with expansion potential in acute multiple sclerosis (MS) relapses following
The FDA Division of Neurology provided positive feedback supporting a regulatory pathway for Privosegtor in acute multiple sclerosis (MS) relapses, addressing a significant unmet medical need The FDA confirmed that
ZUG, Switzerland, July 02, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis" or the "Company"), a global biopharmaceutical company focused on innovations addressing
